![ZS Pharma Logo](/news-release/logo/304118/0/304118.jpg?lastModified=12%2F09%2F2016%2022%3A59%3A48&size=2)
ZS Pharma Announces New Employment Inducement Grants
December 09, 2015 08:00 ET
|
ZS Pharma
SAN MATEO, Calif., Dec. 9, 2015 (GLOBE NEWSWIRE) -- ZS Pharma, Inc. (Nasdaq:SPH), today announced that on December 7, 2015 the compensation committee of its board of directors granted stock options to...
![ZS Pharma Logo](/news-release/logo/304118/0/304118.jpg?lastModified=12%2F09%2F2016%2022%3A59%3A48&size=2)
ZS Pharma Announces New Employment Inducement Grants
November 10, 2015 18:12 ET
|
ZS Pharma
SAN MATEO, Calif., Nov. 10, 2015 (GLOBE NEWSWIRE) -- ZS Pharma, Inc. (Nasdaq:ZSPH), today announced that on November 10, 2015 the compensation committee of its board of directors granted stock options...
![ZS Pharma Logo](/news-release/logo/304118/0/304118.jpg?lastModified=12%2F09%2F2016%2022%3A59%3A48&size=2)
ZS Pharma Announces Positive Interim Results From a Long-Term Safety Study of ZS-9
November 07, 2015 13:00 ET
|
ZS Pharma
SAN MATEO, Calif., Nov. 7, 2015 (GLOBE NEWSWIRE) -- ZS Pharma, Inc. (Nasdaq:ZSPH), today presented interim results from ZS005, a long-term safety and efficacy study of ZS-9 (sodium zirconium...
![ZS Pharma Logo](/news-release/logo/304118/0/304118.jpg?lastModified=12%2F09%2F2016%2022%3A59%3A48&size=2)
ZS Pharma Announces Upcoming Poster Presentation of Interim Results From Its Long-Term Safety Study of ZS-9
October 19, 2015 08:00 ET
|
ZS Pharma
-- ZS005 study accepted as late-breaking poster presentation at American Society of Nephrology's Kidney Week 2015 --
-- Additional ZS-9 and hyperkalemia poster presentations also highlighted...
![ZS Pharma Logo](/news-release/logo/304118/0/304118.jpg?lastModified=12%2F09%2F2016%2022%3A59%3A48&size=2)
ZS Pharma Corporate Statement
September 10, 2015 17:31 ET
|
ZS Pharma
SAN MATEO, Calif., Sept. 10, 2015 (GLOBE NEWSWIRE) -- ZS Pharma, Inc. (Nasdaq:ZSPH), today confirmed that it has participated in preliminary discussions with Actelion Ltd. (OTC:ALIOF) regarding a...
![ZS Pharma Logo](/news-release/logo/304118/0/304118.jpg?lastModified=12%2F09%2F2016%2022%3A59%3A48&size=2)
ZS Pharma Reports Second Quarter 2015 Financial Results and Provides Corporate Update
August 06, 2015 16:05 ET
|
ZS Pharma
REDWOOD CITY, Calif., Aug. 6, 2015 (GLOBE NEWSWIRE) -- ZS Pharma, Inc. (Nasdaq:ZSPH), today reported its financial results for the second quarter ended June 30, 2015, and provided an overview of...
![ZS Pharma Logo](/news-release/logo/304118/0/304118.jpg?lastModified=12%2F09%2F2016%2022%3A59%3A48&size=2)
ZS Pharma Announces FDA Acceptance of ZS-9 New Drug Application
July 29, 2015 16:01 ET
|
ZS Pharma
REDWOOD CITY, Calif., July 29, 2015 (GLOBE NEWSWIRE) -- ZS Pharma, Inc. (Nasdaq:ZSPH), today announced that its New Drug Application (NDA) for ZS-9 (sodium zirconium cyclosilicate) for the treatment...
![ZS Pharma Logo](/news-release/logo/304118/0/304118.jpg?lastModified=12%2F09%2F2016%2022%3A59%3A48&size=2)
ZS Pharma Names Jeffrey Farrow as Chief Financial Officer
June 16, 2015 08:00 ET
|
ZS Pharma
REDWOOD CITY, Calif., June 16, 2015 (GLOBE NEWSWIRE) -- ZS Pharma, Inc. (Nasdaq:ZSPH), a biopharmaceutical company focused on the development and commercialization of highly selective, non-absorbed...
![ZS Pharma Logo](/news-release/logo/304118/0/304118.jpg?lastModified=12%2F09%2F2016%2022%3A59%3A48&size=2)
ZS Pharma Announces Participation at Upcoming Investor Conferences
May 28, 2015 08:00 ET
|
ZS Pharma
REDWOOD CITY, Calif., May 28, 2015 (GLOBE NEWSWIRE) -- ZS Pharma, Inc. (Nasdaq:ZSPH), a biopharmaceutical company focused on the development and commercialization of highly selective, non-absorbed...
![ZS Pharma Logo](/news-release/logo/304118/0/304118.jpg?lastModified=12%2F09%2F2016%2022%3A59%3A48&size=2)
ZS Pharma Submits New Drug Application to U.S. Food and Drug Administration for ZS-9 for the Treatment of Hyperkalemia
May 26, 2015 16:00 ET
|
ZS Pharma
REDWOOD CITY, Calif., May 26, 2015 (GLOBE NEWSWIRE) -- ZS Pharma, Inc. (Nasdaq:ZSPH), a biopharmaceutical company focused on the development and commercialization of highly selective, non-absorbed...